About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Stim2tm1.1Kuro
targeted mutation 1.1, Tomohiro Kurosaki
MGI:5008479
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Stim1tm1Kuro/Stim1tm1Kuro
Stim2tm1.1Kuro/Stim2tm1.1Kuro
Cd79atm1(cre)Reth/Cd79a+ 		involves: BALB/c * C57BL/6 MGI:5008567
cn2
 		Stim2tm1.1Kuro/Stim2tm1.1Kuro
Cd79atm1(cre)Reth/Cd79a+ 		involves: BALB/c * C57BL/6 MGI:5008568


Genotype
MGI:5008567
cn1
Allelic
Composition		 Stim1tm1Kuro/Stim1tm1Kuro
Stim2tm1.1Kuro/Stim2tm1.1Kuro
Cd79atm1(cre)Reth/Cd79a+
Genetic
Background		 involves: BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd79atm1(cre)Reth mutation (3 available); any Cd79a mutation (22 available)
Stim1tm1Kuro mutation (0 available); any Stim1 mutation (46 available)
Stim2tm1.1Kuro mutation (0 available); any Stim2 mutation (42 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
immune system phenotype ( J:172608 )
N
• mice exhibit normal B cell development
increased CD4-positive, alpha-beta T cell number ( J:172608 )
• following immunization with MOG35-55
increased CD8-positive, alpha-beta T cell number ( J:172608 )
• following immunization with MOG35-55
increased regulatory T cell number ( J:172608 )
• following immunization with MOG35-55
abnormal B cell physiology ( J:172608 )
• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice
• B cells treated with anti-IgM, anti-IgM and IL4, or anti-IgM and anti-CD40 exhibit reduced survival compared with control cells
• however, B cell treated with anti-CD40 or LPS exhibit normal survival and B cell antibody response is normal
decreased B cell proliferation ( J:172608 )
• B cells treated anti-IgM fail to exhibit proliferation unlike control cells
• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells
• however, B cell proliferation stimulated by anti-CD40 or LPS is normal
increased interferon-gamma secretion ( J:172608 )
• in splenocytes following immunization with MOG35-55
decreased interleukin-10 secretion ( J:172608 )
• following stimulation with PMA and ionomycin, LPS, anti-IgM and anti-CD40, or anti-IgM and LPS
increased interleukin-10 secretion ( J:172608 )
• in splenocytes following immunization with MOG35-55
increased interleukin-17 secretion ( J:172608 )
• in splenocytes following immunization with MOG35-55
increased susceptibility to experimental autoimmune encephalomyelitis ( J:172608 )
• following immunization with MOG35-55, mice exhibit increased inflammatory cells infiltration (CD8+ and CD4+ T cells, T regulatory cells), demyelination, and cytokine production (IFN-gamma, IL17, and IL10) compared with control mice

nervous system
demyelination ( J:172608 )
• following immunization with MOG35-55

hematopoietic system
increased CD4-positive, alpha-beta T cell number ( J:172608 )
• following immunization with MOG35-55
increased CD8-positive, alpha-beta T cell number ( J:172608 )
• following immunization with MOG35-55
increased regulatory T cell number ( J:172608 )
• following immunization with MOG35-55
abnormal B cell physiology ( J:172608 )
• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice
• B cells treated with anti-IgM, anti-IgM and IL4, or anti-IgM and anti-CD40 exhibit reduced survival compared with control cells
• however, B cell treated with anti-CD40 or LPS exhibit normal survival and B cell antibody response is normal
decreased B cell proliferation ( J:172608 )
• B cells treated anti-IgM fail to exhibit proliferation unlike control cells
• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells
• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

cellular
decreased B cell proliferation ( J:172608 )
• B cells treated anti-IgM fail to exhibit proliferation unlike control cells
• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells
• however, B cell proliferation stimulated by anti-CD40 or LPS is normal




Genotype
MGI:5008568
cn2
Allelic
Composition		 Stim2tm1.1Kuro/Stim2tm1.1Kuro
Cd79atm1(cre)Reth/Cd79a+
Genetic
Background		 involves: BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd79atm1(cre)Reth mutation (3 available); any Cd79a mutation (22 available)
Stim2tm1.1Kuro mutation (0 available); any Stim2 mutation (42 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
immune system phenotype ( J:172608 )
N
• B cell proliferation in response to anti-IgM, anti-CD40, and LPS is normal
abnormal B cell physiology ( J:172608 )
• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

hematopoietic system
abnormal B cell physiology ( J:172608 )
• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/16/2024
MGI 6.23 		The Jackson Laboratory